Literature DB >> 18435965

Effect of successful alcohol septal ablation on microvascular function in patients with obstructive hypertrophic cardiomyopathy.

Osama I I Soliman1, Marcel L Geleijnse, Michelle Michels, Pieter A Dijkmans, Attila Nemes, Bas M van Dalen, Wim B Vletter, Patrick W Serruys, Folkert J ten Cate.   

Abstract

We hypothesized that relief of obstruction in patients with hypertrophic cardiomyopathy (HC) by percutaneous transluminal septal myocardial ablation (PTSMA) improves microvascular dysfunction by relief of extravascular compression. Microvascular dysfunction in obstructive HC is related to extravascular compression by increased left ventricular (LV) mass and LV end-diastolic pressure. The study included 14 patients with obstructive HC (mean age 55+/-12 years, 11 men) who underwent successful PTSMA and 14 healthy volunteers (mean age 31+/-4 years, 11 men). LV hemodynamics (by Doppler echocardiography) and intramyocardial flow dynamics (by adenosine myocardial contrast echocardiography) were evaluated in healthy volunteers and before and 6 months after PTSMA in patients with HC. LV end-diastolic pressure was estimated from the ratio of transmitral early LV filling velocity to early diastolic mitral annular velocity. PTSMA reduced the invasively measured LV outflow tract gradient (119+/-35 vs 17+/-16 mm Hg, p<0.0001) and LV end-diastolic pressure (23+/-3 vs 16+/-2 mm Hg, p<0.001). Six months after PTSMA, myocardial flow reserve improved (2.73+/-0.56 vs 3.21+/-0.49, p<0.001), but did not normalize compared with healthy controls (vs 3.95+/-0.77, p<0.001). Also, septal hyperemic endo-to-epi myocardial blood flow ratio improved (0.70+/-0.11 vs 0.92+/-0.07, p<0.001). Changes in LV end-diastolic pressure, LV mass index, and LV outflow tract peak systolic gradient correlated well with changes in hyperemic perfusion (all p<0.05). In conclusion, microvascular dysfunction improves after PTSMA due to relief of extravascular compression forces.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18435965     DOI: 10.1016/j.amjcard.2007.12.032

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

1.  Cardiomyopathies: a revolution in molecular medicine and cardiac imaging.

Authors:  F J Ten Cate
Journal:  Neth Heart J       Date:  2009-12       Impact factor: 2.380

Review 2.  Hypertrophic cardiomyopathy in 2013: Current speculations and future perspectives.

Authors:  Georgios K Efthimiadis; Efstathios D Pagourelias; Thomas Gossios; Thomas Zegkos
Journal:  World J Cardiol       Date:  2014-02-26

3.  The risk of non-sustained ventricular tachycardia after percutaneous alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy.

Authors:  Mariusz Klopotowski; Lidia Chojnowska; Lukasz A Malek; Renata Maczynska; Krzysztof Kukula; Marcin Demkow; Adam Witkowski; Maciej Dabrowski; Maciej Karcz; Rafal Baranowski; Beata Kusmierczyk-Droszcz; Mariusz Kruk; Jacek Jamiolkowski; Mariusz Kusmierczyk; Lukasz Szumowski; Witold Ruzyllo
Journal:  Clin Res Cardiol       Date:  2010-02-11       Impact factor: 5.460

4.  Comparison of clinical presentation, left ventricular morphology, hemodynamics, and exercise tolerance in obese versus nonobese patients with hypertrophic cardiomyopathy.

Authors:  Marco Canepa; Lars L Sorensen; Iraklis Pozios; Veronica L Dimaano; Hong-Chang Luo; Aurelio C Pinheiro; James B Strait; Claudio Brunelli; M Roselle Abraham; Luigi Ferrucci; Theodore P Abraham
Journal:  Am J Cardiol       Date:  2013-10-15       Impact factor: 2.778

5.  Impact of alcohol septal ablation on left anterior descending coronary artery blood flow in hypertrophic obstructive cardiomyopathy.

Authors:  Willem G van Dockum; Paul Knaapen; Mark B M Hofman; Joost P A Kuijer; Folkert J ten Cate; Jurrien M ten Berg; Aernout M Beek; Jos W R Twisk; Albert C van Rossum
Journal:  Int J Cardiovasc Imaging       Date:  2009-02-22       Impact factor: 2.357

6.  Long-term prognostic value of coronary flow velocity reserve in patients with hypertrophic cardiomyopathy: 9-year follow-up results from SZEGED study.

Authors:  Attila Nemes; Erika Balázs; Osama I I Soliman; Róbert Sepp; Miklós Csanády; Tamás Forster
Journal:  Heart Vessels       Date:  2009-09-27       Impact factor: 2.037

Review 7.  Role of left ventricular twist mechanics in cardiomyopathies, dance of the helices.

Authors:  Floris Kauer; Marcel Leonard Geleijnse; Bastiaan Martijn van Dalen
Journal:  World J Cardiol       Date:  2015-08-26

Review 8.  Coronary microvascular dysfunction: an update.

Authors:  Filippo Crea; Paolo G Camici; Cathleen Noel Bairey Merz
Journal:  Eur Heart J       Date:  2013-12-23       Impact factor: 29.983

9.  Determinants of myocardial energetics and efficiency in symptomatic hypertrophic cardiomyopathy.

Authors:  Stefan A J Timmer; Tjeerd Germans; Marco J W Götte; Iris K Rüssel; Pieter A Dijkmans; Mark Lubberink; Jurrien M ten Berg; Folkert J ten Cate; Adriaan A Lammertsma; Paul Knaapen; Albert C van Rossum
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-13       Impact factor: 9.236

Review 10.  Targets for therapy in sarcomeric cardiomyopathies.

Authors:  Jil C Tardiff; Lucie Carrier; Donald M Bers; Corrado Poggesi; Cecilia Ferrantini; Raffaele Coppini; Lars S Maier; Houman Ashrafian; Sabine Huke; Jolanda van der Velden
Journal:  Cardiovasc Res       Date:  2015-01-29       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.